Volume 11, Number 8—August 2005
Research
Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use
Conan MacDougall*, Spencer E. Harpe*, J. Patrick Powell*, Christopher K. Johnson†, Michael B. Edmond*, and Ron E. Polk*
Figure 2
Figure 2. . A) Changes in fluoroquinolone use (x axis) and resistance in Pseudomonas aeruginosa (y axis) for 9 hospitals with complete data, 1999–2003. Origin is median values of fluoroquinolone use and resistance in 1999. DDD/1,000 PD, defined daily doses/1,000 patient-days. FQ-R PSA, fluoroquinolone-resistant P. aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus. B) Changes in fluoroquinolone use (x axis) and resistance (y axis) in S. aureus for 9 hospitals with complete data, 1999–2003.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.